PJ003

Indication: Gout

Gout is a disorder characterized by Monosodium Urate (MSU) in the blood and tissues. In gout, crystals of uric acid are deposited in the joints, where they cause a type of arthritis called gouty arthritis.Hyperuricemia is associated with the development and progression of gout.

This product is a new kind of PEGylated uric acid oxidase which can effectively reduce blood uric acid and dissolve the crystal caused by MUS deposition.

This product is a category 1 of therapeutic biological products, developed by the MAS-PEG platform of PEG-BIO, has entered the phase I clinical trial.Its long-actingefficacy and lowimmunogenicity make it available for the long-term use.

PJ004

Indication: Idiopathic Thrombocytopenic Purpura (ITP); Chemotherapy-induced Thrombocytopenia(CIT）

This product is a category 1 of therapeutic biological products developed by the TE-Peptides platform. It based on platelet mimic peptide, specific coupling with activated PEG, which can achieve the long-term promotion of platelet count in peripheral blood.Weekly administration for ITP and once per chemotherapy cycleadministration for CIT has entered the investigational new drug application.

PJ017

Indication: Acute Lymphoblastic Leukemia（ALL） 

This product isa novel asparaginase mutant obtained throughspecific directional  PEGylation after computer simulation.Druggability study has been completed. It mainly proposedto treatacute lymphoblastic leukemia.

PJ008

Indication: Phenylketonuria

Phenylketonuria, also called PKU, is a rare inherited disorder that causes an amino acid called Phenylalanine (PA) to build up in the body. PKU is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine.

This product developed throughspecific directional PEGylation after gene modification by the MAS-PEG platform.The structure has been screened and evaluated in vivo.It can be administered subcutaneously once a week and low immunogenicity.

PJ016

Indication: Cancer

Arginine isrestrictive amino acid for tumor cells growth. This product based on Arginine degrading enzyme, coupling PEG to eliminate arginine in human bodyfor a long time. Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction. This product developed bythe MAS-PEG platform and evaluation in vivo has been completed.